Literature DB >> 8117920

Inhibition of topoisomerase I function by nitidine and fagaronine.

L K Wang1, R K Johnson, S M Hecht.   

Abstract

The benzophenanthridine alkaloids nitidine and fagaronine were characterized as inhibitors of topoisomerase I function. In common with the antitumor agent camptothecin, both nitidine and fagaronine stabilized the covalent binary complex formed between calf thymus topoisomerase I and DNA. The effects of these compounds were readily apparent at 0.15-0.3 microM concentrations. Both nitidine and fagaronine inhibited the topoisomerase I-mediated relaxation of supercoiled pSP64 plasmid DNA more effectively than camptothecin; unlike camptothecin, both of these benzophenanthridine alkaloids also bound directly to and mediated the unwinding of B-form DNA. Nitidine and fagaronine were also studied in comparison with camptothecin to determine the sequence specificity of DNA breaks produced from a 32P-end-labeled duplex in the presence of topoisomerase I. All three compounds produced very similar cleavage patterns. The specificity of nitidine and fagaronine for inhibiting topoisomerase I function was studied by measuring the effects of the compounds on the unknotting of P4 DNA by calf thymus topoisomerase II. Moderate inhibition of topoisomerase II-mediated unknotting was obtained, but only in the presence of high (i.e., 40 microM) concentrations of nitidine and fagaronine. In comparison, doxorubicin inhibited topoisomerase II to the same extent as nitidine and fagaronine when it was employed at 2.5 microM concentration and was strongly inhibitory when employed at 10 microM concentration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8117920     DOI: 10.1021/tx00036a010

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  13 in total

1.  Induction of apoptosis by 3-amino-6-(3-aminopropyl)-5,6-dihydro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline via modulation of MAPKs (p38 and c-Jun N-terminal kinase) and c-Myc in HL-60 human leukemia cells.

Authors:  Eun-Jung Park; Evgeny Kiselev; Martin Conda-Sheridan; Mark Cushman; John M Pezzuto
Journal:  J Nat Prod       Date:  2011-12-07       Impact factor: 4.050

Review 2.  Biophysical aspects and biological implications of the interaction of benzophenanthridine alkaloids with DNA.

Authors:  Motilal Maiti; Gopinatha Suresh Kumar
Journal:  Biophys Rev       Date:  2009-08-25

3.  Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.

Authors:  M Del Poeta; S F Chen; D Von Hoff; C C Dykstra; M C Wani; G Manikumar; J Heitman; M E Wall; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Fluorescence properties of selected benzo[c]phenanthridines.

Authors:  Kamil Motyka; Jakub Stýskala; Petr Cankař; Jan Hlaváč
Journal:  J Fluoresc       Date:  2014-05-06       Impact factor: 2.217

5.  Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site.

Authors:  Qasim A Khan; Daniel S Pilch
Journal:  J Mol Biol       Date:  2006-10-13       Impact factor: 5.469

6.  Quinoline alkaloids as intercalative topoisomerase inhibitors.

Authors:  Kendall G Byler; Chen Wang; William N Setzer
Journal:  J Mol Model       Date:  2009-05-08       Impact factor: 1.810

7.  Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.

Authors:  Xiao-Ru Zhang; Hao-Wen Wang; Wen-Lin Tang; Yu Zhang; Hui Yang; De-Xuan Hu; Azhar Ravji; Christophe Marchand; Evgeny Kiselev; Kwabena Ofori-Atta; Keli Agama; Yves Pommier; Lin-Kun An
Journal:  J Med Chem       Date:  2018-10-31       Impact factor: 7.446

8.  Dibenzo[c,h][1,5]naphthyridinediones as topoisomerase I inhibitors: design, synthesis, and biological evaluation.

Authors:  Evgeny Kiselev; Nicholas Empey; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Org Chem       Date:  2012-05-15       Impact factor: 4.354

9.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

10.  Secondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs.

Authors:  Supriya Baikar; Nutan Malpathak
Journal:  Pharmacogn Rev       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.